Back to top

crispr: Archive

Zacks Equity Research

CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?

CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.

VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change CSTLNegative Net Change